#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteosarcoma recurrent Langerhans' cell histiocytosis Carcinoid syndrome Short stature Glycogen storage disease type V Isodicentric chromosome 15 syndrome Chronic graft versus host disease in intestine Stargardt's disease Growth hormone deficiency Thromboangiitis obliterans Angiosarcoma metastatic Adrenoleukodystrophy Angiosarcoma non-metastatic Follicular lymphoma stage II Progressive familial intrahepatic cholestasis More trials…

    Learn about Rare Diseases

    Loeys-Dietz syndrome – Diagnostics Pulmonary fibrosis – Basic Information KBG syndrome – Diagnostics Hereditary motor and sensory neuropathy – Life with Disease Erdheim-Chester disease – Treatment Factor IX deficiency – Life with Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Chondrosarcoma metastatic – Trials in Disease Osteosarcoma Glomerulonephritis membranous – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Batoprotafib Elivaldogene Autotemcel Diphenhydramine Hydrochloride AZD5335 Regn7508 ABY-271 Sodium Ascorbate Hyoscine Butylbromide ZODASIRAN Hydroxypropyl Cellulose Lf Emavusertib Pamidronate Disodium Apixaban Azenosertib Blu-222 Diltiazem Procarbazine Fluticasone ZINC GLUCONATE Cefuroxime Sodium More therapies…

    Learn about Your Condition

    T-cell lymphoma Autoimmune hepatitis Factor IX deficiency Sinusitis bacterial Glomerulonephritis Colorectal adenocarcinoma Colorectal cancer stage II Childhood asthma Breast cancer female Urticaria cholinergic Oropharyngeal cancer recurrent Porphyria non-acute Tachypnoea Neurotrophic keratopathy Multiple system atrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer

  • Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Tucatinib
    • Eribulin Mesylate
    Spain

  • A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    • Gastric cancer
    • Ovarian cancer
    Italy The Netherlands

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Inavolisib
    • Anastrozole
    • Anhydrous Docetaxel
    Belgium Finland France Germany Italy Poland +1

  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    Investigated Drugs:
    • Inavolisib
    • Fulvestrant
    • Ribociclib
    France Germany Italy Poland Spain

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Carboplatin
    • Gemcitabine Hydrochloride
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study of inavolisib and fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Inavolisib
    • Fulvestrant
    Belgium Spain
1 2 3 … 28
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!